| # | Title | Journal | Year | Citations |
|---|
| 1 | ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer | Journal of Clinical Oncology | 2019 | 643 |
| 2 | A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing | Science | 2018 | 641 |
| 3 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma | New England Journal of Medicine | 2021 | 473 |
| 4 | A Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Comparing Early (7 Day) Corticosteroid Cessation Versus Long-Term, Low-Dose Corticosteroid Therapy | Annals of Surgery | 2008 | 420 |
| 5 | Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy | Journal of Clinical Oncology | 2019 | 404 |
| 6 | Purification and Identification of p68 RNA Helicase Acting as a Transcriptional Coactivator Specific for the Activation Function 1 of Human Estrogen Receptor α | Molecular and Cellular Biology | 1999 | 339 |
| 7 | Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations | Pain | 2016 | 270 |
| 8 | Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study | Lancet Oncology, The | 2016 | 210 |
| 9 | Perceived knowledge among patients cared for by nephrologists about chronic kidney disease and end-stage renal disease therapies | Kidney International | 2008 | 202 |
| 10 | Extensions to the Visual Predictive Check to facilitate model performance evaluation | Journal of Pharmacokinetics and Pharmacodynamics | 2008 | 171 |
| 11 | Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery | Journal of Infectious Diseases | 2013 | 171 |
| 12 | EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma | Journal of Clinical Oncology | 2020 | 159 |
| 13 | Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial | Lancet Infectious Diseases, The | 2018 | 141 |
| 14 | Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial | Lancet Oncology, The | 2021 | 122 |
| 15 | Population Pharmacokinetics of Micafungin in Pediatric Patients and Implications for Antifungal Dosing | Antimicrobial Agents and Chemotherapy | 2007 | 99 |
| 16 | Postmarketing Safety Surveillance | Drug Safety | 2013 | 91 |
| 17 | Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project) | BMJ, The | 2022 | 90 |
| 18 | NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods | Molecular and Cellular Proteomics | 2020 | 87 |
| 19 | The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models | European Journal of Pharmacology | 2000 | 80 |
| 20 | The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women | Neurourology and Urodynamics | 2015 | 76 |
| 21 | Two Years Postconversion From a Prograf-Based Regimen to a Once-Daily Tacrolimus Extended-Release Formulation in Stable Kidney Transplant Recipients | Transplantation | 2007 | 74 |
| 22 | Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia | Journal of Clinical Oncology | 2022 | 73 |
| 23 | A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections | Clinical Infectious Diseases | 2015 | 72 |
| 24 | The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients | Journal of Thoracic and Cardiovascular Surgery | 2021 | 67 |
| 25 | Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure | European Journal of Pharmacology | 1999 | 65 |
| 26 | Predictive Value of Brain Natriuretic Peptides in Patients on Peritoneal Dialysis | Clinical Journal of the American Society of Nephrology: CJASN | 2008 | 63 |
| 27 | TRPA1 agonists delay gastric emptying in rats through serotonergic pathways | Naunyn-Schmiedeberg's Archives of Pharmacology | 2009 | 59 |
| 28 | Release of neutrophil elastase and its role in tissue injury in acute inflammation: effect of the elastase inhibitor, FR134043 | European Journal of Pharmacology | 1999 | 58 |
| 29 | Stability: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team | AAPS Journal | 2014 | 58 |
| 30 | NMDA receptor type 2D gene as target for estrogen receptor in the brain | Molecular Brain Research | 1999 | 53 |
| 31 | The alkaline single cell electrophoresis assay with eight mouse organs: results with 22 mono-functional alkylating agents (including 9 dialkyl N-nitrosoamines) and 10 DNA crosslinkers | Mutation Research - Genetic Toxicology and Environmental Mutagenesis | 2000 | 53 |
| 32 | Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy | Blood | 2022 | 52 |
| 33 | In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist | European Journal of Pharmacology | 1999 | 51 |
| 34 | Involvement of the 5-HT3 receptor in CRH-induced defecation in rats | American Journal of Physiology - Renal Physiology | 1998 | 50 |
| 35 | Assessing Renal Function With Daclizumab Induction and Delayed Tacrolimus Introduction in Liver Transplant Recipients | Transplantation | 2010 | 50 |
| 36 | Detection of DNA lesions induced by chemical mutagens by the single cell gel electrophoresis (Comet) assay | Mutation Research - Genetic Toxicology and Environmental Mutagenesis | 1998 | 48 |
| 37 | Conversion From Cyclosporine to Tacrolimus in Patients at Risk for Chronic Renal Allograft Failure: 60-Month Results of the CRAF Study | Transplantation | 2008 | 48 |
| 38 | Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden | Menopause | 2021 | 48 |
| 39 | Cost Effectiveness of Tumour Necrosis Factor-?? Inhibitors as First-Line Agents in Rheumatoid Arthritis | Pharmacoeconomics | 2006 | 47 |
| 40 | Once-Daily Tacrolimus Extended Release Formulation: Experience at 2 Years Postconversion From a Prograf-Based Regimen in Stable Liver Transplant Recipients | Transplantation | 2007 | 47 |
| 41 | Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas | Clinical Cancer Research | 2018 | 44 |
| 42 | Anti-inflammatory and analgesic effects of a novel pyrazole derivative, FR140423 | European Journal of Pharmacology | 1999 | 43 |
| 43 | Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials | Prostate Cancer and Prostatic Diseases | 2017 | 43 |
| 44 | Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH) | European Urology Focus | 2020 | 42 |
| 45 | Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells | Oncotarget | 2019 | 41 |
| 46 | Effects of a nonpeptide bradykinin B2 receptor antagonist, FR167344, on different in vivo animal models of inflammation | British Journal of Pharmacology | 1997 | 40 |
| 47 | The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats | Metabolism: Clinical and Experimental | 2000 | 37 |
| 48 | Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis | Journal of Antimicrobial Chemotherapy | 2017 | 37 |
| 49 | Possible inhibitory mechanism of FK506 (tacrolimus hydrate) ointment for atopic dermatitis based on animal models | European Journal of Pharmacology | 1999 | 36 |
| 50 | The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice | Metabolism: Clinical and Experimental | 2000 | 36 |
